VYNE Therapeutics reports positive Phase 1a SAD data for VYN202; no drug-related adverse events

VYNE Therapeutics Inc.

VYN202 well tolerated across all dose groups; no serious or drug-related AEs, no clinically significant lab/ECG abnormalities.
PK results showed dose-dependent exposure of VYN202 in plasma and urine across all doses tested.
PD activity observed: increased HEXIM1 (target engagement) and inhibitory effect on inflammatory biomarkers for psoriasis and rheumatoid arthritis.
Dosing in the multiple ascending dose (MAD) portion of Phase 1a has begun; results expected Q4 2024.
CEO David Domzalski highlighted milestone for the company's BD2-selective BET inhibitor platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.